EditForce is developing novel RNA-targeted medicines using the PPR platform technology, enabling precise single nucleotide substitution (C>U, U>C) without gRNA. The compact PPR protein gene size allows AAV delivery, and has shown effectiveness in cultured cells. We are building a pipeline of drugs that utilize our technology, primarily in the areas of CNS diseases and rare diseases.
From vaccines and immunotherapies to protein replacement and cell reprogramming, interest in mRNA manufacturing has surged. Decades before the pandemic, Roche CustomBiotech supplied nucleotides and enzymes for mRNA production. We work with pioneering mRNA companies to develop and manufacture needed raw material solutions. In collaboration with therapeutic manufacturers, our portfolio has evolved to meet the changing needs of the mRNA field. Always abreast of market developments, Roche CustomBiotech enables a new generation of mRNA therapeutics. Our guiding tenet is to minimize variation of products built on our raw materials by ensuring best quality, high performance within narrow tolerances, and reliable delivery.
Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.